



## Compass Therapeutics to Participate in Upcoming May Investor Events

May 12, 2026

BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of May.

**Details are as follows:**

### **H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ**

**Date:** Tuesday, May 19, 2026

**Time:** 12:00 PM ET

**Webcast Link:** <https://journey.ct.events/view/bc55d2f9-d121-4f7d-8129-1f69f201bd7f>

### **2026 Stifel Virtual Targeted Oncology Forum**

**Date:** Wednesday, May 20, 2026

**Time:** 11:30 AM ET

**Webcast Link:** <https://event.summitcast.com/view/SScpdhHfwE8g9WsS8WcTax/QuhrzDf8Wdgui7i3FhuDb6>

**Virtual/Replay availability:** Presentations will be archived on Compass' [Events](#) page.

Compass' management will be available for one-on-one meetings during all events. Interested investors should contact their respective representatives to request meetings.

### **About Compass Therapeutics**

Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, MA. Compass is a clinical-stage, oncology-focused biopharmaceutical company discovering and developing proprietary antibody-based therapeutics to treat multiple diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system and tumor growth. Compass has a robust pipeline of novel product candidates designed to target multiple key biological pathways to drive an effective anti-tumor response, including angiogenesis modulation, immune activation within the tumor microenvironment, and reduction of tumor-driven immunosuppression. The company is advancing discovery candidates through clinical development to commercial-stage assets. For more information, visit [www.compasstherapeutics.com](http://www.compasstherapeutics.com).

### **Investor Contact**

[ir@compasstherapeutics.com](mailto:ir@compasstherapeutics.com)

### **Media Contact**

Anna Gifford, Chief of Staff

[media@compasstherapeutics.com](mailto:media@compasstherapeutics.com)

617-500-8099